### COPY FOR IB



# **PCT**


ricC'D	2 6 NOV 2004	
WIPC	PCT	_

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70)

Applicants on specific Stanford			·- · · · · · · · · · · · · · · · · · ·		
Applicant's or agent's file reference PAKIST03141	FOR FURTHER ACTION  SeeNotificationofTransmittalofInternationalPreliminary Examination Report (Form PCT/IPEA/416)				
International application No.	International filing date(day/m	onth/year)	Priority date (day/month	(year)	
PCT/KR2003/001441	21 JULY 2003 (21.07.20		20 JULY 2002 (20.07.2	002)	
International Patent Classification (IPC) or national classification and IPC  IPC7 A61K 31/245  Applicant					
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY et al					
<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> </ol>					
2. This REPORT consists of a total	of 4 sheets, inclu	ding this cover shee	et.		
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
These annexes consist of a total	ofsheets.				
3. This report contains indications re	elating to the following items:				
I X Basis of the report					
II Priority					
III Non-establishment	of opinion with regard to novelty	, inventive step and	l industrial applicability		
IV Lack of unity of inv	ention			·	
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
VI Certain documents of	cited				
VII Certain defects in th	e international application				
VIII Certain observations	VIII Certain observations on the international application				
··					
Date of submission of the demand	Date	of completion of th	is report		
19 FEBRUARY 2004	(19.02.2004)	09 NOVEMBE	R 2004 (09.11.2004)		
Name and mailing address of the IPEA/	0	orized officer		Alde	
Korean Intellectual Property 920 Dunsan-dong, Seo-gu, i Republic of Korea		KIM, Hee Jin			
Facsimile No. 82-42-472-7140		phone No. 82-42-4	81-5412		





PCT/KR2003/001441

L	I. Basis of the report					
1.	1. With regard to the elements of the international application:*					
Ì	X	the international application as originally filed				
		the description:				
		pages, as originally filed pages				
		pages, filed with the demand pages, filed with the letter of				
		the claims:				
	Ш	pages, as originally filed				
		pages, as amended (together with any statment) under Article 19				
		pages, filed with the demand pages, filed with the letter of				
1		the drawings:				
		pages, as originally filed pages, filed with the demand				
	_	pages, filed with the letter of				
		the sequence listing part of the description:				
ĺ		pages, as originally filed				
ĺ		pages, filed with the demand pages, filed with the letter of,				
ŀ						
2.	With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language English which is					
		the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).				
	X	the language of publication of the international application (under Rule 48.3(b)).				
		the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/ or 55.3).				
3.	Wit prel	h regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international iminary examination was carried out on the basis of the sequence listing:				
		contained inthe international application in written form.				
		filed together with the international application in computer readable form.				
		furnished subsequently to this Authority in written form.				
		furnished subsequently to this Authority in computer readable form				
		The statement that the subsequently furnished written sequence listing does not go beyond the disc losure in the international applicationas as filed has been furinshed.				
		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.				
4.		The amendments have resulted in the cancellation of:				
		the description, pages				
		the claims, Nos.				
		the drawings, sheets				
5.						
		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**				
	Replacin this	cement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 0.17).				
**	Any re	eplacement sheet containing such amendments must be referred to under item I and annexed to this report.				

V. I	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial	applicability:
•	citations and explanations supporting such statement	pp. roub, roug,

1.	Statement			
	Novelty (N)	Claims	1-11	YES
		Claims		NO
	Inventive step (IS)	Claims	1-11	YES
		Claims		МО
	Industrial applicability (IA)	Claims	1-11	YES
		Claims		No

2. Citations and explanations (Rule 70.7)

Reference is made to the following documents:

D1: US 4978772

D2: Alimentary Pharmacology and Therapeutics, 15(3), pp.355-361, 2001

D3: Naunyn-Schmiedeberg's Archives of Pharmacology, 359(5), pp.420-427, 1999

D4: British Journal of Pharmacology, 117(3), pp.463-470, 1996

The present invention relates to a use of octylonium bromide to increase cellular uptake of drugs.

D1 relates to a use of octylonium bromide for local applications in the gastrointestinal tract of the digestive system to obtain the arrest of the motility of the gastrointestinal tract. D2 discloses that octylonium bromide is a smooth muscle relaxant in irritable bowel syndrome. D3 describes that octylonium bromide reduces stimulated motility of intestinal smooth muscle by multiple action mechanisms. D4 discloses that octylonium bromide is a potent blocker of neuronal nicotinic acetylcholine receptors.


#### 1. Novelty

None of the cited documents discloses a use of octylonium bromide as an absorption enhancer of drugs by inhibition of p-glycoprotein.

Accordingly, the present invention can be considered novel.

(Continued on Supplemental Sheet.)





PCT/KR2003/001441

Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient)

Continuation of:

## 2. Inventive Step

The skilled person would not have found an incentive to use octylonium bromide as an absorption enhancer because controlling the motility and tension of the intestine has no relationships with the inhibition of p-glycoprotein.

Therefore, the present invention is considered to involve an inventive step.

3. Industrial applicability

The present invention possesses industrial applicability.